Verona Pharma (VRNA)
Verona Pharma Statistics
Share Statistics
Verona Pharma has 84.63M shares outstanding. The number of shares has increased by 734.97% in one year.
| Shares Outstanding | 84.63M |
| Shares Change (YoY) | 734.97% |
| Shares Change (QoQ) | 727.32% |
| Owned by Institutions (%) | 10.53% |
| Shares Floating | 74.18M |
| Failed to Deliver (FTD) Shares | 1.37K |
| FTD / Avg. Volume | 0.1% |
Short Selling Information
The latest short interest is 9.13M, so 10.73% of the outstanding shares have been sold short.
| Short Interest | 9.13M |
| Short % of Shares Out | 10.73% |
| Short % of Float | 11.19% |
| Short Ratio (days to cover) | 10.01 |
Valuation Ratios
The PE ratio is -21.84 and the forward PE ratio is 143.71. Verona Pharma's PEG ratio is -0.11.
| PE Ratio | -21.84 |
| Forward PE | 143.71 |
| PS Ratio | 89.56 |
| Forward PS | 4.4 |
| PB Ratio | 18.51 |
| P/FCF Ratio | -30.99 |
| PEG Ratio | -0.11 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Verona Pharma.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 10.63, with a Debt / Equity ratio of 0.01.
| Current Ratio | 10.63 |
| Quick Ratio | 10.48 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | -0.02 |
| Debt / FCF | -0.02 |
| Interest Coverage | -6.57 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $202.29K |
| Profits Per Employee | $-829.75K |
| Employee Count | 209 |
| Asset Turnover | 0.09 |
| Inventory Turnover | 0.41 |
Taxes
| Income Tax | 10.29M |
| Effective Tax Rate | -6.31% |
Stock Price Statistics
The stock price has increased by 282.63% in the last 52 weeks. The beta is 0.16, so Verona Pharma's price volatility has been higher than the market average.
| Beta | 0.16 |
| 52-Week Price Change | 282.63% |
| 50-Day Moving Average | 62.49 |
| 200-Day Moving Average | 41.69 |
| Relative Strength Index (RSI) | 50.54 |
| Average Volume (20 Days) | 1.37M |
Income Statement
In the last 12 months, Verona Pharma had revenue of 42.28M and earned -173.42M in profits. Earnings per share was -0.27.
| Revenue | 42.28M |
| Gross Profit | 39.7M |
| Operating Income | -154.63M |
| Net Income | -173.42M |
| EBITDA | -138.53M |
| EBIT | -139.59M |
| Earnings Per Share (EPS) | -0.27 |
Balance Sheet
The company has 399.76M in cash and 2.36M in debt, giving a net cash position of 397.4M.
| Cash & Cash Equivalents | 399.76M |
| Total Debt | 2.36M |
| Net Cash | 397.4M |
| Retained Earnings | -562.4M |
| Total Assets | 474.24M |
| Working Capital | 410.89M |
Cash Flow
In the last 12 months, operating cash flow was -122.2M and capital expenditures 0, giving a free cash flow of -122.2M.
| Operating Cash Flow | -122.2M |
| Capital Expenditures | 0 |
| Free Cash Flow | -122.2M |
| FCF Per Share | -0.19 |
Margins
Gross margin is 93.89%, with operating and profit margins of -365.73% and -410.18%.
| Gross Margin | 93.89% |
| Operating Margin | -365.73% |
| Pretax Margin | -385.84% |
| Profit Margin | -410.18% |
| EBITDA Margin | -327.65% |
| EBIT Margin | -365.73% |
| FCF Margin | -289.04% |
Dividends & Yields
VRNA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for VRNA is $72, which is 19.7% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $72 |
| Price Target Difference | 19.7% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
Scores
| Altman Z-Score | 9.68 |
| Piotroski F-Score | 3 |